Personalized radiation dosing may improve prostate cancer therapy

NCT ID NCT07370597

Recruiting now Knowledge-focused Sponsor: Jules Bordet Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether measuring the exact radiation dose delivered to tumors can predict which patients with advanced prostate cancer will respond to a targeted radioactive therapy called Lu-177 PSMA. Researchers will track 110 men over 12 weeks to see if dose calculations after the first treatment cycle can identify non-responders early. The goal is to personalize treatment by adjusting doses or cycles for each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium-177 PSMA radioligand therapy
What this could lead to: If successful, this could allow doctors to personalize radiation doses for prostate cancer patients, potentially improving response rates and reducing ineffective treatments.
What could go wrong: This is an early-stage observational study (110 participants) that does not test a new treatment but rather a prediction method. The approach may not reliably predict outcomes, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER (ADENOCARCINOMA)

Contacts and locations

Locations

Institut Jules Bordet
RECRUITING

Brussels, 1070, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.